Evaluation of Potential Off-label Use of Dabigatran Etexilate in Europe
Phase of Trial: Phase IV
Latest Information Update: 17 Dec 2017
Price : $35 *
At a glance
- Drugs Dabigatran etexilate (Primary)
- Indications Embolism and thrombosis; Stroke
- Focus Therapeutic Use
- Sponsors Boehringer Ingelheim
- 27 May 2016 Status changed from recruiting to completed.
- 22 Feb 2016 Planned End Date changed from 1 Dec 2015 to 1 Mar 2016 as reported by ClinicalTrials.gov record.
- 22 Feb 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Mar 2016 as reported by ClinicalTrials.gov record.